ASCO GI 2023 NAPOLI-3 Randomized, Open-Label Phase 3 Study: Liposomal Irinotecan + 5-Fluorouracil/Leucovorin + Oxaliplatin (NALIRIFOX) vs. nab-Paclitaxel + Gemcitabine in Treatment-Naïve Patients With mPDAC

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

UCLA Health

https://www.uclahealth.org/

At UCLA Health, we provide the best health care, using the latest medical technology — healing humankind one patient at a time.

12th Annual UCLA-Mellinkoff GI and Hepatology Symposium
Personalized Nutrition in Primary Care 2024
2023 Heart Failure Symposium
2023 UCLA ECMO and Life Support Symposium
11th Annual UCLA-Mellinkoff GI and Hepatology Symposium
15th Annual UCLA Liver Diseases Symposium
Neurosurgery
Nephrology
Cardiovascular
Oncology
Liver Grand Rounds
Liver Hour
Gastroenterology
Events
Advanced Lung Disease and Lung Transplantation Symposium 2023
16th Annual UCLA Liver Diseases Symposium
Personalized Nutrition 2022
2024 Advanced Lung Disease and Lung Transplantation Symposium

Playback speed

10 seconds

ASCO GI 2023 NAPOLI-3 Randomized, Open-Label Phase 3 Study: Liposomal Irinotecan + 5-Fluorouracil/Leucovorin + Oxaliplatin (NALIRIFOX) vs. nab-Paclitaxel + Gemcitabine in Treatment-Naïve Patients With mPDAC

By ASCO GI 2023 Conference Coverage FEATURING Zev A. Wainberg

0 views

February 1, 2023

Comments 0

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Oncology